Titre : Tumeurs des voies biliaires

Tumeurs des voies biliaires : Questions médicales fréquentes

Termes MeSH sélectionnés :

Neoadjuvant Therapy
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Tumeurs des voies biliaires : Questions médicales les plus fréquentes", "headline": "Tumeurs des voies biliaires : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Tumeurs des voies biliaires : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-20", "dateModified": "2025-04-14", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Tumeurs des voies biliaires" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Tumeurs de l'appareil digestif", "url": "https://questionsmedicales.fr/mesh/D004067", "about": { "@type": "MedicalCondition", "name": "Tumeurs de l'appareil digestif", "code": { "@type": "MedicalCode", "code": "D004067", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C06.301" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Tumeurs des canaux biliaires", "alternateName": "Bile Duct Neoplasms", "url": "https://questionsmedicales.fr/mesh/D001650", "about": { "@type": "MedicalCondition", "name": "Tumeurs des canaux biliaires", "code": { "@type": "MedicalCode", "code": "D001650", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C06.301.120.250" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Tumeurs du cholédoque", "alternateName": "Common Bile Duct Neoplasms", "url": "https://questionsmedicales.fr/mesh/D003138", "about": { "@type": "MedicalCondition", "name": "Tumeurs du cholédoque", "code": { "@type": "MedicalCode", "code": "D003138", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C06.301.120.250.250" } } } ] }, { "@type": "MedicalWebPage", "name": "Tumeurs de la vésicule biliaire", "alternateName": "Gallbladder Neoplasms", "url": "https://questionsmedicales.fr/mesh/D005706", "about": { "@type": "MedicalCondition", "name": "Tumeurs de la vésicule biliaire", "code": { "@type": "MedicalCode", "code": "D005706", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C06.301.120.401" } } } ], "about": { "@type": "MedicalCondition", "name": "Tumeurs des voies biliaires", "alternateName": "Biliary Tract Neoplasms", "code": { "@type": "MedicalCode", "code": "D001661", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Yasuni Nakanuma", "url": "https://questionsmedicales.fr/author/Yasuni%20Nakanuma", "affiliation": { "@type": "Organization", "name": "Department of Diagnostic Pathology, Shizuoka Cancer Center, Shizuoka, Japan; Department of Diagnostic Pathology, Fukui Prefecture Saiseikai Hospital, Japan. Electronic address: nakanumayasu@gmail.com." } }, { "@type": "Person", "name": "Takashi Sugino", "url": "https://questionsmedicales.fr/author/Takashi%20Sugino", "affiliation": { "@type": "Organization", "name": "Department of Diagnostic Pathology, Shizuoka Cancer Center, Shizuoka, Japan." } }, { "@type": "Person", "name": "Yasunori Sato", "url": "https://questionsmedicales.fr/author/Yasunori%20Sato", "affiliation": { "@type": "Organization", "name": "Department of Human Pathology, Kanazawa University School of Medicine, Kanazawa, Japan." } }, { "@type": "Person", "name": "Hans-Olov Adami", "url": "https://questionsmedicales.fr/author/Hans-Olov%20Adami", "affiliation": { "@type": "Organization", "name": "Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden." } }, { "@type": "Person", "name": "Gary E Fraser", "url": "https://questionsmedicales.fr/author/Gary%20E%20Fraser", "affiliation": { "@type": "Organization", "name": "School of Public Health, Loma Linda University, Loma Linda, California." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Rectal MRI Interpretation After Neoadjuvant Therapy.", "datePublished": "2022-09-08", "url": "https://questionsmedicales.fr/article/36073323", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/jmri.28426" } }, { "@type": "ScholarlyArticle", "name": "Adjuvant Therapy After Neoadjuvant Therapy for Esophageal Cancer: Who Needs It?", "datePublished": "2022-08-23", "url": "https://questionsmedicales.fr/article/35997269", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/SLA.0000000000005679" } }, { "@type": "ScholarlyArticle", "name": "Emerging Indications for Neoadjuvant Systemic Therapies in Cutaneous Malignancies.", "datePublished": "2024-07-23", "url": "https://questionsmedicales.fr/article/39189198", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/medsci12030035" } }, { "@type": "ScholarlyArticle", "name": "The Effect of Neoadjuvant Therapy on Esophagectomy for cT2N0M0 Esophageal Adenocarcinoma.", "datePublished": "2023-10-26", "url": "https://questionsmedicales.fr/article/37884701", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1245/s10434-023-14441-z" } }, { "@type": "ScholarlyArticle", "name": "Neoadjuvant therapy in non-small cell lung cancer.", "datePublished": "2023-08-01", "url": "https://questionsmedicales.fr/article/37532102", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.critrevonc.2023.104080" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies de l'appareil digestif", "item": "https://questionsmedicales.fr/mesh/D004066" }, { "@type": "ListItem", "position": 3, "name": "Tumeurs de l'appareil digestif", "item": "https://questionsmedicales.fr/mesh/D004067" }, { "@type": "ListItem", "position": 4, "name": "Tumeurs des voies biliaires", "item": "https://questionsmedicales.fr/mesh/D001661" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Tumeurs des voies biliaires - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Tumeurs des voies biliaires", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-04-30", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Tumeurs des voies biliaires", "description": "Comment diagnostique-t-on une tumeur des voies biliaires ?\nQuels tests sanguins sont utiles pour le diagnostic ?\nQuelle est l'importance de l'IRM dans le diagnostic ?\nPeut-on utiliser la cholangiographie pour le diagnostic ?\nQuels symptômes peuvent alerter sur une tumeur ?", "url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Neoadjuvant+Therapy&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Tumeurs des voies biliaires", "description": "Quels sont les symptômes courants des tumeurs biliaires ?\nLa jaunisse est-elle un symptôme fréquent ?\nPeut-on avoir des démangeaisons avec une tumeur biliaire ?\nLes nausées sont-elles un symptôme associé ?\nComment la douleur abdominale se manifeste-t-elle ?", "url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Neoadjuvant+Therapy&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Tumeurs des voies biliaires", "description": "Peut-on prévenir les tumeurs des voies biliaires ?\nQuels facteurs de risque sont évitables ?\nL'alimentation joue-t-elle un rôle ?\nLes infections chroniques augmentent-elles le risque ?\nLe tabagisme est-il un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Neoadjuvant+Therapy&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Tumeurs des voies biliaires", "description": "Quels sont les traitements possibles pour ces tumeurs ?\nLa chirurgie est-elle toujours possible ?\nQuand la chimiothérapie est-elle recommandée ?\nLa radiothérapie est-elle efficace ?\nY a-t-il des traitements ciblés disponibles ?", "url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Neoadjuvant+Therapy&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Tumeurs des voies biliaires", "description": "Quelles complications peuvent survenir ?\nL'obstruction biliaire est-elle grave ?\nLes infections sont-elles fréquentes ?\nQuelles sont les conséquences des métastases ?\nPeut-on prévenir les complications ?", "url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Neoadjuvant+Therapy&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Tumeurs des voies biliaires", "description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de tumeurs biliaires ?\nLes maladies hépatiques augmentent-elles le risque ?\nL'exposition à l'arsenic est-elle un risque ?\nLes antécédents familiaux jouent-ils un rôle ?", "url": "https://questionsmedicales.fr/mesh/D001661?mesh_terms=Neoadjuvant+Therapy&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on une tumeur des voies biliaires ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic se fait par imagerie (échographie, IRM) et biopsie." } }, { "@type": "Question", "name": "Quels tests sanguins sont utiles pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent les marqueurs tumoraux comme l'ACE et les tests de fonction hépatique." } }, { "@type": "Question", "name": "Quelle est l'importance de l'IRM dans le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "L'IRM permet de visualiser les tumeurs et d'évaluer leur extension." } }, { "@type": "Question", "name": "Peut-on utiliser la cholangiographie pour le diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la cholangiographie permet de visualiser les voies biliaires et détecter des obstructions." } }, { "@type": "Question", "name": "Quels symptômes peuvent alerter sur une tumeur ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des douleurs abdominales, jaunisse, et démangeaisons peuvent indiquer une tumeur." } }, { "@type": "Question", "name": "Quels sont les symptômes courants des tumeurs biliaires ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent douleur abdominale, jaunisse, et perte de poids." } }, { "@type": "Question", "name": "La jaunisse est-elle un symptôme fréquent ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la jaunisse est fréquente et résulte d'une obstruction des voies biliaires." } }, { "@type": "Question", "name": "Peut-on avoir des démangeaisons avec une tumeur biliaire ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les démangeaisons peuvent survenir en raison de l'accumulation de bile." } }, { "@type": "Question", "name": "Les nausées sont-elles un symptôme associé ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les nausées peuvent être présentes en raison de l'irritation du système digestif." } }, { "@type": "Question", "name": "Comment la douleur abdominale se manifeste-t-elle ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "La douleur est souvent localisée dans la partie supérieure droite de l'abdomen." } }, { "@type": "Question", "name": "Peut-on prévenir les tumeurs des voies biliaires ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais éviter l'hépatite et l'alcool peut aider." } }, { "@type": "Question", "name": "Quels facteurs de risque sont évitables ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "L'alcoolisme et l'exposition à des produits chimiques sont des facteurs évitables." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation saine peut réduire le risque de maladies hépatiques, mais pas spécifiquement." } }, { "@type": "Question", "name": "Les infections chroniques augmentent-elles le risque ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les infections chroniques comme l'hépatite B et C augmentent le risque." } }, { "@type": "Question", "name": "Le tabagisme est-il un facteur de risque ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme est associé à un risque accru de plusieurs cancers, y compris biliaires." } }, { "@type": "Question", "name": "Quels sont les traitements possibles pour ces tumeurs ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la chirurgie, la chimiothérapie et la radiothérapie." } }, { "@type": "Question", "name": "La chirurgie est-elle toujours possible ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Non, la chirurgie dépend de la taille et de l'emplacement de la tumeur." } }, { "@type": "Question", "name": "Quand la chimiothérapie est-elle recommandée ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La chimiothérapie est souvent utilisée pour les tumeurs avancées ou inopérables." } }, { "@type": "Question", "name": "La radiothérapie est-elle efficace ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La radiothérapie peut soulager les symptômes et est utilisée en complément." } }, { "@type": "Question", "name": "Y a-t-il des traitements ciblés disponibles ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des traitements ciblés peuvent être utilisés selon le type de tumeur." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent l'obstruction biliaire, l'infection et la métastase." } }, { "@type": "Question", "name": "L'obstruction biliaire est-elle grave ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut entraîner des douleurs sévères et des infections hépatiques." } }, { "@type": "Question", "name": "Les infections sont-elles fréquentes ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les infections peuvent survenir en raison de l'obstruction des voies biliaires." } }, { "@type": "Question", "name": "Quelles sont les conséquences des métastases ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les métastases peuvent affecter d'autres organes et compliquer le traitement." } }, { "@type": "Question", "name": "Peut-on prévenir les complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être évitées par un suivi médical régulier." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, l'hépatite chronique et l'exposition à des toxines." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque de tumeurs biliaires ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque augmente avec l'âge, surtout après 50 ans." } }, { "@type": "Question", "name": "Les maladies hépatiques augmentent-elles le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les maladies hépatiques chroniques comme la cirrhose augmentent le risque." } }, { "@type": "Question", "name": "L'exposition à l'arsenic est-elle un risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à l'arsenic est associée à un risque accru de cancers biliaires." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de cancers peuvent augmenter le risque." } } ] } ] }

Sources (10000 au total)

Adjuvant Therapy After Neoadjuvant Therapy for Esophageal Cancer: Who Needs It?

We hypothesized that, on average, patients do not benefit from additional adjuvant therapy after neoadjuvant therapy for locally advanced esophageal cancer, although subsets of patients might. Therefo... Although neoadjuvant therapy has become the treatment of choice for locally advanced esophageal cancer, the value of adding adjuvant therapy is unknown.... From 1970 to 2014, 22,123 patients were treated for esophageal cancer at 33 centers on 6 continents (Worldwide Esophageal Cancer Collaboration), of whom 7731 with adenocarcinoma or squamous cell carci... Patients received a small survival benefit from adjuvant therapy (3.2±10 months over the subsequent 10 years for adenocarcinoma, 1.8±11 for squamous cell carcinoma). Consistent benefit occurred in ypT... Adjuvant therapy after neoadjuvant therapy has value primarily for patients with more advanced esophageal cancer. Because the benefit is often small, patients considering adjuvant therapy should be co...

The Effect of Neoadjuvant Therapy on Esophagectomy for cT2N0M0 Esophageal Adenocarcinoma.

For cT2N0M0 esophageal adenocarcinomas, the effects of neoadjuvant chemoradiotherapy (NT) on surgical outcomes and the oncological benefits to the patients are debatable. In this study, we investigate... The National Cancer Database was queried (2010-2019) for patients with cT2N0M0 esophageal adenocarcinoma undergoing esophagectomy. After propensity-matching to adjust for differences in patient and tu... This study included 3413 patients, of whom 2359 (69%) received NT, and 1054 (31%) S. In contrast to those who underwent S, in the matched cohort, patients treated with NT had comparable conversion rat... NT does not appear to increase technical complexity or to adversely affect postoperative outcomes after esophagectomy. Furthermore, minimally invasive esophagectomy is feasible following NT, with comp...

Neoadjuvant Therapy for Duodenal and Ampullary Adenocarcinoma: A Systematic Review.

The role of systemic therapy in the management of ampullary (AA) and duodenal adenocarcinoma (DA) remains poorly understood. This study sought to synthesize current evidence supporting the use of neoa... The study searched PubMed, Cochrane Library (Wiley), Embase (Elsevier), CINAHL (EBSCO), and ClinicalTrials.gov databases for observational or randomized studies published between 2002 and 2022 evaluat... From the 347 abstracts identified in this study, 29 reports were reviewed in full, and 15 were included in the final review. The selected studies published from 2007 to 2022 were retrospective. Eight ... Evidence supporting the use of NAT in AA and DA is weak. No randomized studies exist, and observational data show mixed results. For patients with DA and AA, NAT appears safe, but better evidence is n...

Patient Preferences for Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma.

Physicians are increasingly recommending neoadjuvant therapy (NT) before surgery for pancreatic ductal adenocarcinoma (PDAC). However, patient preferences for and opinions regarding NT are poorly unde... Survivors and caregivers from a national PDAC patient advocacy organization completed an online survey assessing preferences for NT versus surgery first (SF) and factors influencing their decision mak... Among 54 participants, 74.1% had a personal history of PDAC. While most patients preferred SF for resectable disease, NT was the preferred treatment approach for borderline resectable, locally advance... Among a national cohort of PDAC survivors and caregivers, the majority preferred SF for resectable PDAC, whereas NT was preferred when the resectability of a tumor was in question. The impact of NT on...